Hepatobiliary Neoplasm Clinical Trial
Official title:
Holographic Augmented Reality Versus Screen Visualisation of 3D Rendering Models for the Pre-operative Evaluation and Planning of Liver Resections
Verified date | February 2024 |
Source | Federico II University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this trial is to compare the evaluation of 3D liver models visualised as holograms with HoloLens 2 and on digital PDF files in HPB surgical trainees. The main questions it aims to answer are: - Do the holographic models allow a superior accuracy in terms of anatomical evaluation and surgical planning? - Is there any difference in terms of time consumed and Task Load Index? Participants will analyse cases through both modalities and answer a questionnaire.
Status | Completed |
Enrollment | 16 |
Est. completion date | February 1, 2024 |
Est. primary completion date | November 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - General Surgery Trainees with at least 6 months experience in HPB surgery Exclusion Criteria: - No informed consent |
Country | Name | City | State |
---|---|---|---|
Italy | Federico II University | Naples |
Lead Sponsor | Collaborator |
---|---|
Federico II University | ICAR (Istituto di Calcolo e Reti ad Alte Prestazioni) - CNR (Consiglio Nazionale delle Ricerche) |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic and planning accuracy | Correctly identify anatomy and appropriate surgical planning Residents' decision-making accuracy when reviewing patient data and 3D liver models using Holograms or on PDF, measured by comparing their performance.
The measurement tool will be a questionnaire consisting of 11 questions, rate of correct answers will be recorded (e.g. 8/10 correct answers) and higher scores mean a better outcome. |
Immediately after completing the evaluation | |
Secondary | Time consumed | Analyse the time spent for the evaluation of the cases and complete the questionnaire Assessed by total time needed to make decision for 15 patient cases in minutes | Immediately after completing the evaluation | |
Secondary | NASA Task Load Index | Analyse the NASA TLI score for each participant to evaluate the cases by conducting a subjective mental workload assessment rating performance across six dimensions to determine an overall workload rating:
Mental demand - how much thinking, deciding, or calculating was required to perform the task. Physical demand - the amount and intensity of physical activity required to complete the task. Temporal demand - the amount of time pressure involved in completing the task. Effort - how hard does the participant have to work to maintain their level of performance? Performance - the level of success in completing the task. Frustration level - how insecure, discouraged, or secure or content the participant felt during the task. Each participant gives a rating for each subscale from 1 (low) to 20 (high) and the TLX will calculate the overall worklaod score between 0 and 100 |
Immediately after completing the evaluation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01020812 -
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT04959630 -
Immersive Virtual Reality Environment for Complex Cognitive Skills Curricular Training in Liver Surgery
|
N/A | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Recruiting |
NCT04010071 -
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
|
Phase 2 | |
Recruiting |
NCT04709445 -
Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses
|
N/A | |
Terminated |
NCT01151761 -
PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT04501913 -
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
|
||
Withdrawn |
NCT03818997 -
Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
|
Phase 2 | |
Completed |
NCT04642664 -
Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer
|
Phase 2 | |
Not yet recruiting |
NCT03760289 -
DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer
|
Phase 2 | |
Terminated |
NCT00767234 -
Permission to Collect Blood Over Time for Research
|
N/A |